Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.41
EW's Cash to Debt is ranked higher than
72% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. EW: 2.41 )
EW' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 2.41

Equity to Asset 0.62
EW's Equity to Asset is ranked higher than
68% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. EW: 0.62 )
EW' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.85
Current: 0.62

0.4
0.85
Interest Coverage 28.65
EW's Interest Coverage is ranked higher than
58% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. EW: 28.65 )
EW' s 10-Year Interest Coverage Range
Min: 1.04   Max: 9999.99
Current: 28.65

1.04
9999.99
F-Score: 7
Z-Score: 10.48
M-Score: -3.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) -43.14
EW's Operating margin (%) is ranked higher than
56% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. EW: -43.14 )
EW' s 10-Year Operating margin (%) Range
Min: -29.23   Max: 23.1
Current: -43.14

-29.23
23.1
Net-margin (%) 34.92
EW's Net-margin (%) is ranked higher than
98% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. EW: 34.92 )
EW' s 10-Year Net-margin (%) Range
Min: -33.83   Max: 34.92
Current: 34.92

-33.83
34.92
ROE (%) 44.89
EW's ROE (%) is ranked higher than
99% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. EW: 44.89 )
EW' s 10-Year ROE (%) Range
Min: -32.69   Max: 43.42
Current: 44.89

-32.69
43.42
ROA (%) 26.06
EW's ROA (%) is ranked higher than
99% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. EW: 26.06 )
EW' s 10-Year ROA (%) Range
Min: -21.38   Max: 26.02
Current: 26.06

-21.38
26.02
ROC (Joel Greenblatt) (%) -123.75
EW's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. EW: -123.75 )
EW' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -168.46   Max: 63.32
Current: -123.75

-168.46
63.32
Revenue Growth (3Y)(%) 15.00
EW's Revenue Growth (3Y)(%) is ranked higher than
89% of the 346 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. EW: 15.00 )
EW' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 15
Current: 15

0
15
EBITDA Growth (3Y)(%) 57.70
EW's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. EW: 57.70 )
EW' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 57.7
Current: 57.7

0
57.7
EPS Growth (3Y)(%) 55.70
EW's EPS Growth (3Y)(%) is ranked higher than
96% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. EW: 55.70 )
EW' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 348.1
Current: 55.7

0
348.1
» EW's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

EW Guru Trades in Q1 2014

Paul Tudor Jones 101,400 sh (New)
Steven Cohen 13,278 sh (+290.76%)
Pioneer Investments 256,068 sh (+42.68%)
Vanguard Health Care Fund 5,324,000 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Steven Cohen 150,000 sh (unchged)
Jim Simons Sold Out
Jana Partners Sold Out
Ron Baron 1,354,511 sh (-11.70%)
Jeremy Grantham 53,446 sh (-21.39%)
Joel Greenblatt 71,689 sh (-39.12%)
» More
Q2 2014

EW Guru Trades in Q2 2014

Jim Simons 19,300 sh (New)
Joel Greenblatt 259,073 sh (+261.38%)
Jeremy Grantham 167,446 sh (+213.30%)
PRIMECAP Management 280,000 sh (unchged)
Vanguard Health Care Fund 4,920,000 sh (-7.59%)
Ron Baron 1,083,004 sh (-20.04%)
Pioneer Investments 203,209 sh (-20.64%)
Paul Tudor Jones 5,000 sh (-95.07%)
» More
Q3 2014

EW Guru Trades in Q3 2014

RS Investment Management 62,460 sh (New)
Steven Cohen 206,300 sh (New)
Paul Tudor Jones 10,112 sh (+102.24%)
Jim Simons 20,900 sh (+8.29%)
Joel Greenblatt 272,994 sh (+5.37%)
Pioneer Investments 195,380 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Jeremy Grantham 150,665 sh (-10.02%)
Vanguard Health Care Fund 4,207,470 sh (-14.48%)
Ron Baron 836,867 sh (-22.73%)
» More
Q4 2014

EW Guru Trades in Q4 2014

Jim Simons 484,500 sh (+2218.18%)
PRIMECAP Management 280,000 sh (unchged)
Steven Cohen Sold Out
RS Investment Management 60,839 sh (-2.60%)
Joel Greenblatt 247,876 sh (-9.20%)
Pioneer Investments 175,690 sh (-10.08%)
Jeremy Grantham 127,469 sh (-15.40%)
Vanguard Health Care Fund 3,402,670 sh (-19.13%)
Ron Baron 576,836 sh (-31.07%)
Paul Tudor Jones 6,196 sh (-38.73%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.10
EW's P/E(ttm) is ranked higher than
93% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 201.60 vs. EW: 19.10 )
EW' s 10-Year P/E(ttm) Range
Min: 11.18   Max: 450
Current: 19.1

11.18
450
Forward P/E 30.96
EW's Forward P/E is ranked higher than
83% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 30.96 )
N/A
PE(NRI) 19.10
EW's PE(NRI) is ranked higher than
93% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 140.40 vs. EW: 19.10 )
EW' s 10-Year PE(NRI) Range
Min: 11.18   Max: 600
Current: 19.1

11.18
600
P/B 7.01
EW's P/B is ranked higher than
55% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. EW: 7.01 )
EW' s 10-Year P/B Range
Min: 2.91   Max: 8.46
Current: 7.01

2.91
8.46
P/S 6.72
EW's P/S is ranked higher than
56% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.68 vs. EW: 6.72 )
EW' s 10-Year P/S Range
Min: 2.21   Max: 7.38
Current: 6.72

2.21
7.38
PFCF 16.65
EW's PFCF is ranked higher than
94% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 16.65 )
EW' s 10-Year PFCF Range
Min: 7.82   Max: 534.25
Current: 16.65

7.82
534.25
POCF 15.16
EW's POCF is ranked higher than
90% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 78.33 vs. EW: 15.16 )
EW' s 10-Year POCF Range
Min: 7.33   Max: 43.32
Current: 15.16

7.33
43.32
PEG 0.68
EW's PEG is ranked higher than
99% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 0.68 )
EW' s 10-Year PEG Range
Min: 0.51   Max: 3.5
Current: 0.68

0.51
3.5
Shiller P/E 44.35
EW's Shiller P/E is ranked higher than
85% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 44.35 )
EW' s 10-Year Shiller P/E Range
Min: 25.28   Max: 69.38
Current: 44.35

25.28
69.38
Current Ratio 5.28
EW's Current Ratio is ranked higher than
87% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. EW: 5.28 )
EW' s 10-Year Current Ratio Range
Min: 1.26   Max: 5.28
Current: 5.28

1.26
5.28
Quick Ratio 4.60
EW's Quick Ratio is ranked higher than
88% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. EW: 4.60 )
EW' s 10-Year Quick Ratio Range
Min: 0.9   Max: 4.6
Current: 4.6

0.9
4.6
Days Inventory 179.05
EW's Days Inventory is ranked higher than
66% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 166.67 vs. EW: 179.05 )
EW' s 10-Year Days Inventory Range
Min: 97.78   Max: 208.39
Current: 179.05

97.78
208.39
Days Sales Outstanding 45.25
EW's Days Sales Outstanding is ranked higher than
92% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.87 vs. EW: 45.25 )
EW' s 10-Year Days Sales Outstanding Range
Min: 38.74   Max: 69.95
Current: 45.25

38.74
69.95

Valuation & Return

vs
industry
vs
history
Price/Net Cash 146.61
EW's Price/Net Cash is ranked higher than
79% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 146.61 )
EW' s 10-Year Price/Net Cash Range
Min: 129.98   Max: 129.98
Current: 146.61

Price/Net Current Asset Value 16.11
EW's Price/Net Current Asset Value is ranked higher than
76% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 327.00 vs. EW: 16.11 )
EW' s 10-Year Price/Net Current Asset Value Range
Min: 11.43   Max: 78.4
Current: 16.11

11.43
78.4
Price/Tangible Book 8.58
EW's Price/Tangible Book is ranked higher than
64% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. EW: 8.58 )
EW' s 10-Year Price/Tangible Book Range
Min: 6.38   Max: 28.78
Current: 8.58

6.38
28.78
Price/DCF (Projected) 2.30
EW's Price/DCF (Projected) is ranked higher than
87% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 2.30 )
EW' s 10-Year Price/DCF (Projected) Range
Min: 1.47   Max: 3.36
Current: 2.3

1.47
3.36
Price/Median PS Value 2.08
EW's Price/Median PS Value is ranked higher than
58% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. EW: 2.08 )
EW' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.06
Current: 2.08

0.39
2.06
Price/Peter Lynch Fair Value 0.77
EW's Price/Peter Lynch Fair Value is ranked higher than
99% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 0.77 )
EW' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.68   Max: 3.89
Current: 0.77

0.68
3.89
Price/Graham Number 2.71
EW's Price/Graham Number is ranked higher than
85% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. EW: 2.71 )
EW' s 10-Year Price/Graham Number Range
Min: 2.29   Max: 33.82
Current: 2.71

2.29
33.82
Earnings Yield (Greenblatt) -6.80
EW's Earnings Yield (Greenblatt) is ranked higher than
55% of the 468 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. EW: -6.80 )
EW' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 7.9
Current: -6.8

1.4
7.9
Forward Rate of Return (Yacktman) 34.83
EW's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 4.94 vs. EW: 34.83 )
EW' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.2   Max: 35.2
Current: 34.83

3.2
35.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EWL.Germany,
Edwards Lifesciences Corp was incorporated in Delaware on September 10, 1999. The Company is the manufacturer of heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. It is also a global leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. It conducts operations worldwide and are managed in the following geographical regions: United States, Europe, Japan and Rest of World. The products and technologies provided by the Company to treat advanced cardiovascular disease or critically ill patients are categorized into the following main areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Company's Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Company's Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. In the Critical Care portfolio, Edwards Lifesciences' products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The Company competes with many companies, including divisions of companies much larger than it and smaller companies that compete in specific product lines or certain geographies. The Company's Surgical Heart Valve Therapy and Transcatheter Heart Valve products are manufactured in California and Utah in the United States, Switzerland, and Singapore. Critical Care products are manufactured primarily in its facilities located in Puerto Rico and the Dominican Republic. The Company's products and technologies are subject to regulation by numerous domestic and foreign government agencies, including the FDA, and various laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of its products and technologies.
» More Articles for EW

Headlines

Articles On GuruFocus.com
Fairly Valued Long-Term Performer – Edwards Lifesciences Mar 23 2015 
East West Petroleum to Renew Normal Course Issuer Bid Jan 27 2015 
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
East West Petroleum Provides Operational Update Dec 16 2014 
Edwards Lifesciences Invests $50 Million in New Heart Failure Technology Dec 10 2014 
East West Petroleum Announces Drilling of Cheal-E6 Well in New Zealand Nov 26 2014 
East West Petroleum Grants Stock Options Nov 14 2014 
East West Petroleum Provides Operational Update for New Zealand Nov 05 2014 
East West Petroleum Announces Results of Annual General Meeting Oct 15 2014 
EW: Potential for Capital Appreciation Oct 03 2014 


More From Other Websites
Varian (VAR) Showcases Edge Radiosurgey at 2015 ChinaMed - Analyst Blog Mar 27 2015
Cepheid's Xpert Ebola Gets FDA's Nod for Emergency Use - Analyst Blog Mar 27 2015
Zacks Industry Outlook Highlights: Boston Scientific, Edwards Lifesciences, Natus Medical, Hologic... Mar 27 2015
Why Edwards Lifesciences (EW) is Poised to Beat Earnings Estimates Again - Tale of the Tape Mar 27 2015
Inogen's Texas Facility Ready, Costs Likely to Scale Down - Analyst Blog Mar 26 2015
Abiomed Attains New 52-Week High on Impella 2.5 Approval - Analyst Blog Mar 25 2015
Abiomed's Impella 2.5 FDA-Approved for PCI Procedures - Analyst Blog Mar 24 2015
Edwards' CEO Addresses Senate Committee On Preserving And Strengthening Medical Device Innovation In... Mar 24 2015
Edwards' CEO Addresses Senate Committee On Preserving And Strengthening Medical Device Innovation In... Mar 24 2015
Varian Opens New Unit in Algeria, Consolidates in North Africa - Analyst Blog Mar 19 2015
Edwards Lifesciences Up on Positive PARTNER Trial Data - Analyst Blog Mar 18 2015
Edwards Lifesciences Corp (EW), QUALCOMM, Inc. (QCOM): David Blood and Al Gore Bet Big on Healthcare... Mar 17 2015
Cramer: Skepticism too thick Mar 16 2015
Cardiology stocks with a pulse Mar 16 2015
How the bulls are playing Edwards Mar 16 2015
Cramer's Mad Dash: Regeneron breaking out Mar 16 2015
SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk... Mar 15 2015
Five-Year Outcomes For High-Risk Sapien Patients Demonstrate Equivalence To Surgery, Durable Valve... Mar 15 2015
Edwards’s Newer, Smaller Heart Valve Lowered Death Risk in Study Mar 15 2015
Five-Year Outcomes For High-Risk Sapien Patients Demonstrate Equivalence To Surgery, Durable Valve... Mar 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK